Position Statement of the Chinese Diabetes Society regarding stem cell therapy for diabetes*
Dalong ZHU
Division of Endocrinology, Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu
Search for more papers by this authorLi CHEN
Department of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong
Search for more papers by this authorTianpei HONG
Department of Endocrinology, Peking University Third Hospital, Beijing, China
Search for more papers by this authorfor the Chinese Diabetes Society
The members of the Expert Committee are as follows (in alphabetical order): Li CHEN, Hongkui DENG, Shaoping DENG, Lixin GUO, Xiaohui GUO, Tianpei HONG, Renming HU, Linong JI, Qiuhe JI, Weiping JIA, Xiaoying LI, Jing LIU, Jinning LOU, Juming LU, Guang NING, Xingwu RAN, Lixin SHI, Guangyao SONG, Dongqi TANG, Haoming TIAN, Changjiang WANG, Jianping WENG, Xinhua XIAO, Yancheng XU, Zhangrong XU, Xiaoli YAO, Li YUAN, Zhiguang ZHOU, and Dalong ZHU.
Search for more papers by this authorDalong ZHU
Division of Endocrinology, Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu
Search for more papers by this authorLi CHEN
Department of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong
Search for more papers by this authorTianpei HONG
Department of Endocrinology, Peking University Third Hospital, Beijing, China
Search for more papers by this authorfor the Chinese Diabetes Society
The members of the Expert Committee are as follows (in alphabetical order): Li CHEN, Hongkui DENG, Shaoping DENG, Lixin GUO, Xiaohui GUO, Tianpei HONG, Renming HU, Linong JI, Qiuhe JI, Weiping JIA, Xiaoying LI, Jing LIU, Jinning LOU, Juming LU, Guang NING, Xingwu RAN, Lixin SHI, Guangyao SONG, Dongqi TANG, Haoming TIAN, Changjiang WANG, Jianping WENG, Xinhua XIAO, Yancheng XU, Zhangrong XU, Xiaoli YAO, Li YUAN, Zhiguang ZHOU, and Dalong ZHU.
Search for more papers by this authorThis statement was perused by all members of the Chinese Diabetes Society (CDS).
References
- 1 International Diabetes Federation. Facts & Figures: Diabetes Prevalence. Available from: http://www.idf.org/search/node/facts%20and%20figures (accessed 29 November 2011).
- 2 American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2008; 31 (Suppl): S55–60.
- 3 Waldron-Lynch F, Herold KC. Advances in type 1 diabetes therapeutics: Immunomodulation and beta-cell salvage. Endocrinol Metab Clin. 2009; 38: 303–17.
- 4 Limbert C, Päth G, Jakob F et al. Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus. Diabetes Res Clin Pract. 2008; 79: 389–99.
- 5 Efrat S. Beta-cell replacement for insulin-dependent diabetes mellitus. Adv Drug Deliv Rev. 2008; 60: 114–23.
- 6 Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg. 2001; 25: 487–96.
- 7 Ming CS, Chen ZH. Progress in pancreas transplantation and combined pancreas–kidney transplantation. Hepatobiliary Pancreat Dis Int. 2007; 6: 17–23.
- 8 Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant. 2005; 19: 433–55.
- 9 Socci C, Orsenigo E, Santagostino I et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. Transplant Proc. 2010; 42: 268–70.
- 10 Fiorina P, Secchi A. Pancreatic islet cell transplant for treatment of diabetes. Endocrinol Metab Clin North Am. 2007; 36: 999–1013.
- 11 Matsumoto S. Islet cell transplantation for type 1 diabetes. J Diabetes. 2010; 2: 16–22.
- 12 James AM, Ricordi C, Hering BJ et al. International trial of the Edmonton Protocol for islet transplantation. N Engl J Med. 2006; 355: 1318–30.
- 13 Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005; 54: 2060–9.
- 14 Borowiak M. The new generation of beta-cells: Replication, stem cell differentiation, and the role of small molecules. Rev Diabet Stud. 2010; 7: 93–104.
- 15 Zulewski H. Differentiation of embryonic and adult stem cells into insulin producing cells. Panminerva Med. 2008; 50: 73–9.
- 16 Liew CG. Generation of insulin-producing cells from pluripotent stem cells: From the selection of cell sources to the optimization of protocols. Rev Diabet Stud. 2010; 7: 82–92.
- 17 Jones PM, Courtney ML, Burns CJ et al. Cell-based treatments for diabetes. Drug Discov Today. 2008; 13: 888–93.
- 18 Xu X, D’Hoker J, Stangé G et al. β cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008; 132: 197–207.
- 19 Bonner-Weir S, Inada A, Yatoh S et al. Transdifferentiation of pancreatic ductal cells to endocrine β-cells. Biochem Soc Trans. 2008; 36: 353–6.
- 20 Voltarelli JC, Couri CE. Stem cell transplantation for type 1 diabetes mellitus. Diabetol Metab Syndr. 2009; 16: 1–4.
- 21 Liu M, Han ZC. Mesenchymal stem cells: Biology and clinical potential in type 1 diabetes therapy. J Cell Mol Med. 2008; 12: 1155–68.
- 22 Kadam SS, Bhonde RR. Islet neogenesis from the constitutively nestin expressing human umbilical cord matrix derived mesenchymal stem cells. Islets. 2010; 2: 112–20.
- 23 Voharelli JC, Couri EB, Boris N et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type l diabetes mellitus. JAMA. 2007; 297: 1568–77.
- 24 Carlos EB, Maria CB, Ana BPL et al. C-Peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301: 1573–9.
- 25 Shen S, Li L, Zhu D et al. Therapeutic effects of autologous hematopoietic stem cell transplantation in one newly-dianosed type 1 diabetes patient. Chinese J Diabet. 2008; 16: 455–7. (In Mandarin.)
- 26 Li L, Shen S, Zhu D et al. Therapeutic effects and safety of autologous hematopoietic stem cell transplantation in newly-dianosed type 1 diabetes patients. Chinese J Diabet. 2010; 18: 752–5. (In Mandarin.)
- 27 Zhang C, Zhu W, Feng Z et al. Preliminary study of autologous bone marrow stem cell transplantation for the treatment of type 1 diabetes. Guangdong Med J. 2004; 25: 1398–9. (In Mandarin.)
- 28 Long M, Zheng H, Tong Q et al. Directional transplantation of autologous bone marrow stem cells to pancreas in 1 case of diabetes. Acta Academiae Medicinae Militaris Tertiae. 2010; 32: 524–32. (In Mandarin.)
- 29 Couri CE, Voltarelli JC. Stem cell therapy for type 1 diabetes mellitus: A review of recent clinical trials. Diabetol Metab Syndr. 2009; 19: 1–5.
- 30 Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005; 65: 3035–9.
- 31 Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2006; 25: 371–9.
- 32 Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007; 67: 9142–9.
- 33 Shih CC, Forman SJ, Chu P et al. Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev. 2007; 16: 893–902.
- 34 Schuldiner M, Itskovitz-Eldor J, Benvenisty N. Selective ablation of human embryonic stem cells expressing a “suicide” gene. Stem Cells. 2003; 21: 257–65.
- 35 Guo T, Hebrok M. Stem cells to pancreatic beta-cells: New sources for diabetes cell therapy. Endocr Rev. 2009; 30: 214–27.
Citing Literature
